Enterprise Value
865.2M
Cash
350.4M
Avg Qtr Burn
-9.852M
Short % of Float
12.11%
Insider Ownership
7.03%
Institutional Own.
38.06%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lupkynis (Voclosporin) Details Lupus nephritis | Approved Update | |
Voclosporin Ophthalmic Solution Details Dry eye syndrome | Failed Discontinued | |
Voclosporin Details Focal segmental glomerulosclerosis | Failed Discontinued |